Letter: Digoxin bioavailability. 1973

C F Baker

UI MeSH Term Description Entries
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001702 Biopharmaceutics The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action. Pharmaceutics,Pharmaceutic

Related Publications

C F Baker
June 1975, Lancet (London, England),
C F Baker
January 1975, Clinical pharmacology and therapeutics,
C F Baker
November 1973, Journal of the American Pharmaceutical Association,
C F Baker
October 1974, Journal of pharmaceutical sciences,
C F Baker
November 1978, Lancet (London, England),
C F Baker
December 1971, The New England journal of medicine,
Copied contents to your clipboard!